Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

[1]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. , 2015, The Lancet. Oncology.

[2]  B. Rapoport,et al.  Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC) , 2015, Supportive Care in Cancer.

[3]  R. Martell,et al.  Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. , 2014 .

[4]  A. Molassiotis,et al.  International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. , 2014, European journal of pharmacology.

[5]  T. Tsukamoto,et al.  Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. , 2014, European journal of pharmacology.

[6]  G. Rossi,et al.  Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone , 2013, Supportive Care in Cancer.

[7]  A. Molassiotis,et al.  The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Lachowicz,et al.  Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets , 2012, Pharmacology Biochemistry and Behavior.

[9]  J. Beaumont,et al.  Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Hardwick,et al.  Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study , 2010, Supportive Care in Cancer.

[13]  P. Hesketh.  Chemotherapy-induced nausea and vomiting. , 2008, The New England journal of medicine.

[14]  R. Gralla,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Lines,et al.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone , 2003, Clinical pharmacology and therapeutics.

[16]  J. Osterhaus,et al.  Quality of life consequences of chemotherapy-induced emesis , 1992, Quality of Life Research.